Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization in 2026??

<< Previous

Bullboard Posts

Next >>

Comment by StevenBirchon Jan 03, 2023 9:25pm

253 Views

Post# 35201926

RE:RE:RE:Commercialization in 2026??

It seems Dr. Mandel was being as conservative as possible, using the timeline of 2026 as if Phase II ran it's course to 125 patients without BTD, AA or having a big pharma partner. But those are all very possible if not likely in the near term as he talks about partnering talks.

As stated I'm sure that there has been interest and it seems the order of events is likely BTD, announcing a partnership then AA which I am sure comes easier with a big pharma partner given the influence we know they have.

Given Dr. Mandel's usually measured comments this article is almost like him shouting from the rooftops about what they have.

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success